You are here:

Archived: standardised allergen extract of grass pollen from Timothy (Phleum pratense) 75,000 SQ-T per oral lyophilisate

Advice

Following a full submission.

Standardised allergen extract of grass pollen 75,000 per oral lyophilisate (Grazax) is not recommended for use within NHS Scotland for the treatment of grass pollen induced rhinitis and conjunctivitis in adult patients with clinically relevant symptoms and diagnosed with a positive skin prick test and/or specific IgE test to grass pollen.

The place in the treatment of seasonal allergic rhinitis, the patient population and the long-term benefits of Grazax® still have to be fully established as evidence from only the first year of a three-year treatment programme has been published. The manufacturer did not present a sufficiently robust economic analysis to gain acceptance by SMC.

The licence holder has indicated their decision to resubmit.

Drug Details

Drug Name: standardised allergen extract of grass pollen from Timothy (Phleum pratense) 75,000 SQ-T per oral lyophilisate
SMC Drug ID: 367/07
Manufacturer: ALK-Abello Ltd
Indication: Grass pollen induced rhinitis and conjunctivitis in adult patients
BNF Category:
Sub Category: 3.4 Antihistamines*** hyposensitisation*** and allergic emergencies
Submission Type: Full submission
Status: Not Recommended
Date Advice Published: 7 May 2007

Current Advice

Resubmission 14 January 2008

Back